Home » QUEST DIAGNOSTICS ACQUIRES MAKER OF INSURE COLORECTAL CANCER SCREENING TEST
QUEST DIAGNOSTICS ACQUIRES MAKER OF INSURE COLORECTAL CANCER SCREENING TEST
Quest Diagnostics Incorporated, a provider of diagnostic testing, information and services, announced that it has completed the acquisition of Enterix, Inc., the privately held Australian-based company that developed and manufactures the InSure Fecal Immunochemical Test (F.I.T.), an FDA-cleared test for use in screening for colorectal cancer and other sources of lower gastrointestinal bleeding, for approximately $43 million in cash. Additional terms of the transaction
were not disclosed.
EndoNurse
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct